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Purpose:
1. To assess health-related quality of life (HRQoL) of adult long term (up to 20 years)
and very long term (>20 years) childhood cancer survivors, compared to the HRQoL
of an age matched Dutch population sample.
2. To evaluate the impact of cancer-related adverse late effects on the functional, psy-
chological and social health of childhood cancer survivors.
Method: The RAND-36 was used to assess HRQoL in all adult (P18 years) survivors
who had attended the long-term follow-up clinic since 1995. The survivors were
divided into two groups based on the length of follow-up: Group LF (long term fol-
low-up, follow-up 620 years, n = 129) and Group VLF (very long-term follow-up, fol-
low-up >20 years, n = 184). Data on diagnosis, treatment and complications were
obtained from medical records. Late effects were graded using the CTCAEv3.
Results: The RAND-36 was completed by 313 (86.2%) out of 363 eligible patients.
Except for higher scores on the subscale Bodily pain, LF patients did not differ signif-
icantly on the RAND-36 subscales from the population sample; VLF patients had sig-
nificant lower scores on the subscales Physical functioning (P = 0.003), Social
functioning, Vitality and General health perception (P < 0.001). Significantly more
VLF patients (P < 0.001) had severe (grade 3 and 4) late effects (47.8%) compared to
LF patients (27.9%). Female gender and especially psycho-social late effects were
inversely related to HRQoL.
Conclusion: Childhood cancer survivors who were diagnosed more than 20 years ago
have lower scores on the RAND 36, and have significantly more severe late effects
than those diagnosed more recently.Patients with longer follow-up are more likely
to become lost to follow-up. Time has come to establish new models of care for adult
childhood cancer survivors, which are more flexible and appropriate to the needs of
adult childhood cancer survivors.
 2006 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved
fax: +31 50 3611671.
.nl (R. Blaauwbroek)..
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1. Introduction
Advances in paediatric cancer therapy have led to long-term
survival of more than 70% of patients treated.1,2 Conse-
quently, there have been a growing number of childhood can-
cer survivors in the last few decades. Along with the
impressive gains in survival, negative long-term conse-
quences related to the disease or its treatment, i.e. adverse
late effects, have been acknowledged in the recent literature
as well. These late effects can seriously impair the survivors’
overall health. It is estimated that physical and/or psychoso-
cial complications will develop in as many as two thirds of
these young adults.3–6 Although not all adult childhood can-
cer survivors appear to suffer from the late sequelae of their
disease and/or treatment, many survivors do seem to experi-
ence problems, and often their tolerance of disability appears
to decline with time. With the increasing number of long-
term childhood cancer survivors, the need to improve their
overall well-being or health-related quality of life (HRQoL) is
becoming even more important and meaningful. ‘Health-re-
lated quality of life’ is seen as a multidimensional psycholog-
ical construct, which includes at least four domains: physical,
cognitive, social and emotional functioning.7 In some recent
studies of young adult survivors of childhood cancer, only
small differences, or no differences at all were found between
the HRQoL of survivors and healthy controls or norm data.8–10
In all of these studies, survivors of childhood cancer are still
young and the mean time since diagnosis is less than 20
years. But less is known about the HRQoL of survivors diag-
nosed more than 20 years ago.
Patients’ perception of their quality of life may change over
time. For example, many cancer patients report benefits from
their illness, ranging from an increased ability to appreciate
each day, to greater feelings of personal strength, such as
more satisfaction with their global quality of life than healthy
comparison groups.11–14 This paradox is considered to reflect
a psychological adaptation that occurs in cancer patients as
well as in patients with other chronic diseases.15 It is possible
that this mechanism will decline as time since diagnosis in-
creases and adverse late affects appear. With advancing age
there is more chance of additional major life events, develop-
ing a functional limitation or experiencing chronic disease,
which may influence the quality of life. We expected that sur-
vivors diagnosed more than 20 years ago might have more
serious late effects and subsequently experience their HRQoL
as worse compared to survivors diagnosed more recently.
The main purpose of this study was to assess HRQoL of
adult long term (up to 20 years) and very long term (>20 years)
survivors of childhood cancer, compared to the HRQoL of a
comparable group of the Dutch population. The second pur-
pose was to grade treatment- and cancer-related late effects
and their impact on the functional, psychological and social
health of the childhood cancer survivors.
2. Patients and methods
The present study was performed at the Division of Pediatric
Oncology of the University Medical Center in Groningen
(UMCG), The Netherlands. Three hundred sixty three survi-
vors were included in this study. The study population wascomposed of 227 childhood cancer survivors and patients
with chemo and/or radiotherapy, who had attended the
long-term follow-up (LTFU) clinic since 1995. In addition an
at-random sample of 136 survivors out of 336 eligible survi-
vors who had been treated in the Department of Pediatric
Oncology in the past, but were not yet involved in any kind
of follow-up, were recalled to the LTFU clinic and included
in this study.
Furthermore, eight bone tumour survivors (osteosarcoma
or Ewing’s sarcoma) who were older than 18 years at the time
of diagnosis and whose chemotherapy at that time had been
delivered by the paediatric oncologist were included as well.
Brain tumour survivors were not included because they are
followed at a separate clinic. All patients were seen by a doc-
tor with special interest in late effects. According to their
diagnosis and treatment in the past, the patients underwent
risk-based evaluations such as hormonal assessments, echo-
cardiography, bone mineral density tests or pulmonary func-
tion tests.
All late effects diagnosed by means of history, physical
examination or testing were recorded in a database. Medical
data on diagnosis, treatment and health problems were ob-
tained from this registry of the local LTFU clinic. To determine
the need for medical and psychosocial care, late effects were
graded in terms of severity and the survivors’ QoL was mea-
sured with the RAND-36. In order to compare the HRQoL be-
tween survivors with different lengths of follow-up, we
divided the study population into a LF group (LTFU 620 years
n = 129)andaVLFgroup (veryLTFU, followup>20yearsn = 184).
The cut-off point of 20 years was based on the fact that to
our knowledge in the literature no HRQoL studies have been
performed that included a significant number of survivors
diagnosed more than 20 years ago.
2.1. Health-related quality of life (HRQoL)
We used the RAND-3616 to assess HRQoL. The RAND-36 is an
internationally used valid and reliable generic self-report
questionnaire to assess HRQoL. It contains eight different
subscales: physical functioning (PF), social functioning (SF),
role limitations due to physical problems (RP), role limitations
due to emotional problems (RE), mental health (MH), vitality
(VT), bodily pain (BP) and general health perception (GH).
For each subscale, scores were coded, summed up and trans-
formed to a scale from 0 (worst health) to 100 (best health).
The questionnaire takes about 10 min to complete. The
instrument has been translated in Dutch17 and has been val-
idated for the Dutch population.18 For the LF patients we used
the mean scores of the available Dutch norm group, aged 18–
34 years (n = 356), and for the VLF patients the mean scores of
the available Dutch norm group, aged 25–44 years (n = 416).
2.2. Grading of late effects
Late effects were graded using the Common Terminology Cri-
teria for Adverse Events, Version 3 (CTCAEv3), developed by
the National Cancer Institute (NCI). The NCI common toxicity
criteria (CTCv1.0) was created in 1983 to aid in the recognition
and grading adverse effects of chemotherapy. It was updated
Table 1 – Demographic and clinical data of 313






Age at studyb 24 (19–45) 32 (21–60)a
Age at diagnosisb 10 (0–27) 5 (0–38)a
Time since diagnosisb 16 (7–20) 26 (21–38)a
Malec 68 (52.7) 94 (51.1)
Type of cancerc
Leukaemia 53 (41.1) 80 (43.5)
Malignant lymphoma 34 (26.4) 24 (13.0)
Bone tumour 12 (9.3) 26 (14.1)
Soft tissue sarcoma 7 (5.4) 16 (8.7)
Wilms’ tumour 10 (7.8) 12 (6.5)
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acute effects.19 The third version of the CTC has been re-
named as common terminology criteria for adverse events v
3.0. The CTCAEv3 represents the first comprehensive, mul-
timodality grading system to include both acute and late
effects.20
The CTCAEv3 grades adverse effects from 0 to 4. Grade 1
effects are minimal and usually asymptomatic. Grade 2 ef-
fects are moderate, are usually symptomatic but do not im-
pair activities of daily living. Grade 3 effects are considered
severe requiring more serious interventions. Grade 4 effects
are potentially life threatening. Low-grade events (Grades 1
and 2) are considered tolerable and manageable and should
be distinguished from severe or very undesirable high-grade
events (Grades 3 and 4).Langerhans cell histiocytosis 3 (2.3) 11(6.0)
Other 10 (7.8) 15 (8.2)
Treatmentc
Cranial radiation 19 (14.7) 78 (42.4)a
Chemotherapy only 70 (54.3) 65 (35.3)a
Radiotherapy only 6 (4.7) 7 (3.8)
Chemo-and radiotherapy 45 (34.9) 108 (58.7)a
Late effectsc
No late effect 45 (34.9) 16 (8.7)a
Mild late effect 48 (37.2) 80 (43.5)
Severe late effect 36 (27.9) 88 (47.8)a
a P < 0.001.
b Years, median (range).
c Number (%).2.3. Analysis
The statistical package for social sciences (SPSS) Windows
version 11.0 was used for the statistical analyses. Descrip-
tive statistics were calculated for all of the variables.
Differences between the mean scores of the RAND-36 in
the survivors groups and the Dutch standard population
were tested with the One-Sample T-test. Differences in
mean scores of the RAND-36 between LF- and VLF patients
were analysed with the Student’s t-test. Categorical vari-
ables were analysed using the Pearson Chi-Square test. Uni-
variate relationships between demographic, medical and
treatment on the one hand, and RAND-36 scores on the
other hand were assessed by Pearsons correlation coeffi-
cients. To investigate which variables predict the survivors
QoL, all significant characteristics identified from univariate
analysis were studied with multiple linear regression analy-
sis. A significance level of P < 0.05 was applied in all the
analyses.
3. Results
The RAND-36 was sent to 363 survivors, who fulfilled the
inclusion criteria and returned, by 313 patients (response rate
86.2%). The characteristics of patients who returned the ques-
tionnaire were compared with the characteristics of those
who did not. The respondents were older (median age 29,
range19–60) than the non-respondents (median age 25, range
20–39) and the time since diagnosis in the respondents was
longer (median duration 23 years, range 7–38) than that in
the non-respondents (median duration 17.5 years, range 9–
34). No significant differences were found in gender, diagno-
sis, age at diagnosis and health problems as registered at
the LTFU clinic.
The demographic and clinical data of the 313 included
LF and VLF survivors are shown in Table 1. The survivors
had been treated for a variety of cancers or LCH. The most
frequent diagnoses were leukaemia, malignant lymphoma,
bone tumour and Wilms’ tumour. Due to the inclusion cri-
teria, VLF patients were older and the time since diagnosis
was longer.
More VLF leukaemia patients had undergone cranial radi-
ation (CR) (42.4%) than LF leukaemia patients (14.7%,P < 0.001) and they had received more often a combination
of chemo-and radiotherapy (58.7% versus 34.9%, P < 0.001).
VLF patients had significant more severe late effects (47.8%)
than LF patients (27.9%, P < 0.001) (Table 1).
3.1. Quality of life (RAND-36)
The outcomes on the various subscales of the RAND-36 for
the standard population, the LF patients, and the VLF patients
are shown in Table 2. LF patients did not score significantly
lower on the RAND-36 subscales compared to the standard
population. On the subscale Bodily pain, they even scored sig-
nificantly better (P < 0.01). VLF survivors showedworse HRQoL
scores in comparison to the standard population on the sub-
scales physical functioning (PF, P < 0.01), social functioning
(SF, P < 0.001), vitality (VT, P < 0.001) and general health per-
ception (GH, P < 0.001).
Fig. 1 shows the differences on the various RAND dimen-
sions between the LF and VLF patients in comparison with
the age matched standard population. Difference scores were
calculated by subtracting mean outcomes of the standard
population from the results of the LF and VLF patients. Nega-
tive difference scores indicate worse outcomes than in the
standard population. Compared with LF patients, VLF pa-
tients scored significantly worse on the subscales PF
(P < 0.01), RP (P < 0.05), VT (P < 0.05) BP (P < 0.001) and GH
(P < 0.05).
In Fig. 2, the difference scores for the various RAND dimen-
sions are shown for patients treated with chemotherapy
Table 2 – Means and standard deviations for the RAND-36 subscales for LF patients, VLF patients and the Dutch
comparison groups LF (18–34 years) and VLF (25–44 years)
LF patients (n = 129) VLF patients (n = 184) Comparison group LF (n = 356) Comparison group V LF (n = 416)
Mean SD Mean SD Mean SD Mean SD
PF 90.6 14.1 85.6a 18.7 90.3 16.6 89.7 16.3
SF 85.2 22.8 83.0b 21.1 88.7 18.3 89.4 17.0
RP 86.4 27.8 78.6 33.8 83.8 31.2 82.7 32.2
RE 87.1 30.2 84.3 32.2 84.6 31.5 84.6 31.5
MH 77.0 16.9 75.9 15.3 76.8 18.7 77.9 17.7
VT 66.7 19.6 62.6b 19.6 69.1 18.8 68.2 18.9
BP 90.1b 16.9 82.8 19.8 85.5 22.8 84.0 22.9
GH 73.5 18.0 67.7b 22.6 77.4 20.0 75.9 20.2
LF: long term follow-up 620 years; VLF: very long-term follow-up >20 years; PF: physical functioning; SF: social functioning; RP: role limitations
due to physical problems; RE: role limitations due to emotional problems; MH: mental health; VT: vitality; BP: bodily pain; GH: general health
perceptions.
a P < 0.01: difference between survivors and comparison group.


















Fig. 1 – Difference in mean RAND scores of LF- (long-term follow-up, 620 years) and VLF patients (very long-term follow-up,
>20 years) compared with an age matched Dutch standard population PF, etc. see Section 2.1.
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comparison with those of the Dutch norm population. Pa-
tients treated with a combination of radio- and chemotherapy
showed lower scores on different subscales of the RAND but
this was only significant for the subscale General health per-
ception compared to those treated with chemotherapy only.
Although leukaemia patients treated with cranial radiation
(n = 85) had lower scores on the RAND-36, they did not differ
significantly from those who did not receive cranial radiation
(n = 48) (Fig. 3).
Except for the bone tumour patients who scored signifi-
cantly lower on the subscale physical functioning (PF) (mean
score PF 71.0 versus 87.4), no significant differences could bedetected between the different diagnoses concerning the re-
sults in the different RAND subscales.
Table 3 shows the regression coefficient b of gender,
age at diagnosis, time since diagnosis and late effects
per organ system for six subscales of the RAND-36. In
general, males appreciate their HRQoL better than fe-
males. The presence of orthopaedic, neurological and psy-
chosocial late effects is negative related with the subscale
physical functioning of the RAND-36 (P < 0.001). Psycho-so-
cial late effects are also negative related to the subscales
social functioning (P < 0.001), mental health (P < 0.001),
vitality (P < 0.001), bodily pain (P < 0.05) and general health


















Fig. 2 – Difference in mean RAND scores of patients treated with chemotherapy and patients treated with a combination of
chemo-and radiotherapy compared with a Dutch standard population PF, etc. see Section 2.1.
126 E U R O P E A N J O U R N A L O F C A N C E R 4 3 ( 2 0 0 7 ) 1 2 2 –1 3 0ative related to the subscales physical functioning
(P < 0.05), social functioning (P < 0.001), vitality (P < 0.01)
and general health perception (P < 0.05). Orthopaedic and
cosmetically late effects are negative related to the sub-













PF SF RP RE
Fig. 3 – Difference in mean RAND scores of leukaemia patients
treated without CR compared with a Dutch standard population3.2. Grading of late effects
Significant more patients in the VLF group had severe
(grades 3 and 4) late effects (88/184, 47.8%) than in the LF




treated with cranial radiation (CR) and leukaemia patients
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Table 4 – Relation between severe late effects and diagnosis or treatment modalities
Type of tumour and treatment Number of patients Severe late effect Grade 3 or 4
N %
Type of tumour
Leukaemia 133 48 36.1
Leukaemia with CR 85 40 47.1
Leukaemia without CR 48 8 16.7
Bone tumour 38 31 81.6
Malignant lymphoma 58 11 19.0
Soft tissue sarcoma 23 12 52.2
Wilms’ tumour 22 5 22.7
Histiocytosis 14 6 42.9
Other 25 11 44.0
Treatment
Survivors treated with chemotherapy 135 37 27.4
Survivors treated with RT and chemotherapy 153 74 48.4
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radiotherapy had more severe late effects (74/153, 48.4%)
than those who had received chemotherapy only (37/135,
27.4%, P < 0.001). Leukaemia patients treated with
cranial radiation (CR) had more severe late effects (40/85,
47.1%) than those who did not receive CR (8/48, 16.7%,
P < 0.001).
Bone tumour and soft tissue sarcoma patients had the
highest incidence of severe late effects (Table 4). The numbers
of sequelae graded according to the CTCAEv3 represent
cumulative data (survivors with multiple late effects).
4. Discussion
Childhood cancer survivors with a follow-up of more than 20
years had significant lower scores on the RAND-36 subscales
physical functioning, vitality, bodily pain and general health
perception and have significantly more severe late effects
than those with follow-up less than 20 years. In agreement
with other studies, the LF group showed only small differ-
ences in HRQoL compared with the Dutch standard group. Pa-
tients treated with a combination of chemo-and radiotherapy
had significant more late effects and lower HRQoL scores than
those who were treated with chemotherapy alone. Female
gender and late effects, especially psychosocial problems,
were negatively related to HRQoL.
It has been stated that persons who have survived a life-
threatening disease find their present life more satisfying as
a result of psychological adaptation.Thismightoccur in cancer
patients as well as in patients with other chronic diseases.14,8
This could explain why LF patients score significantly bet-
ter on the subscale bodily pain than the Dutch comparison
group. It seems plausible that this mechanism may decline
when time since diagnosis increases.
LF patients had different treatment protocols than VLF pa-
tients and the supportive care during treatment has improved
over the years. The number of patients who received cranial
radiation was higher in the VLF group, which might partly ex-
plain our finding that VLF patients have more severe late ef-
fects and lower scores on the RAND. But also if we exclude
patients who received cranial radiation from the analyses,we still find significant lower scores on various subscales of
the RAND-36 in the VLF group compared with the LF group.
It seems likely that long-term effects in adults differ from
those experienced in childhood or adolescence. New issues
may come up, like worries about fertility, health of offspring
and future health problems of their children. Negative conse-
quences consistently reported in the literature concern job
discrimination, difficulties in obtaining health and life insur-
ance,21,22 as well as lower rates of marriage and parenthood.23
Also medical problems associated with aging may exhibit an
earlier onset or more accelerated course following certain
cancer therapies such as cardiovascular disease, osteoporosis
or second malignancy.
Long-term follow-up of childhood cancer survivors is
highly recommended by the American Cancer Society.6 Regu-
larly scheduled surveillance with early detection and treat-
ment of late effects, combined with education concerning
risk modification theoretically should have a positive impact
on the quality of life and long term health of adult survivors.
From the literature, we know that the percentage of survi-
vors involved in follow-up programs decreases with age of the
survivor. Adult survivors do not fit in paediatric clinics, and
when they grow up, marry and change their name and/or ad-
dress, they are likely to be ‘lost to follow-up’. In the CCSS
analysis, only 31% of survivors who were 18–19 years of age
at the time of interview had seen a health care provider at a
childhood cancer centre in the previous two years. This per-
centage steadily decreased with age to 17% of those who were
35 years or older.24
Our study shows that survivors diagnosed more than 20
years ago have a higher percentage of severe late effects
(47.8%) and perceive their QoL to be worse than survivors
diagnosed more recently. In general, only a minority of VLF-
survivors will attend a LTFU clinic. For these elder survivors
it is important to establish new systems for follow-up, which
are more flexible and appropriate to the needs of adult
survivors.
Most survivors are in contact with a general practitioner
(GP), but the average GP is not particularly aware of the risks
of this population. GPs will increasingly come in contact with
these patients, up to 8–9 in 2010.25 Involving GPs in a shared
E U R O P E A N J O U R N A L O F C A N C E R 4 3 ( 2 0 0 7 ) 1 2 2 –1 3 0 129care program for long-term follow-up will increase their
knowledge about the unique needs of childhood cancer survi-
vors. It is important that GPs are well informed before their
first interaction with a patient who is a childhood cancer sur-
vivor. Only then GPs will not miss the opportunities to recog-
nise late effects and to intervene if possible. GPs are trained to
promote good health practices and avoidance of risk-taking
behaviours; this might help to decrease risky behaviour
among cancer survivors. A Combined Model for long-term fol-
low-up as described by Friedman,26 in which long-term fol-
low-up of childhood cancer survivors is a co-ordinated
effort of the Cancer clinic and the patients own GP, might
be successful, but is not yet studied.
Such amodel could facilitate the necessary transition from
paediatric-based care to adult care as childhood cancer survi-
vorsmature into adulthood. At the same time, GPswill become
more prepared for the specific needs of the increasing number
of adult survivors of childhood cancer.
Several limitationsmust be regarded in the interpretationof
this study. Firstly, eight personswere older than 45 years, how-
ever, their exclusion did not change the outcome of this study.
Secondly brain tumour survivors were not included in this
study and there is an over-representation of leukaemia pa-
tients. Comparedwith leukaemia survivors, survivors of brain
tumours are more likely to report adverse health.27 In addi-
tion the instrument usedwas the RAND-36, which is a generic
outcome measure focusing on health-related quality of life.
To investigate the functioning of survivors more thoroughly,
more specific questionnaires are needed. There are also other
important aspects of the functioning of survivors as educa-
tional achievement, employment, marital status, additionally
experienced life events and comorbidities, which we left out
of the current study.
Conflict of interest statement
‘All authors declare that they have nothing to declare’. Ethical
approval was not required.Acknowledgements
The authors are indebted to Dr. L.C Kremer, Emma Children’s
Hospital, Academic Medical Center, Amsterdam, for her
methodological advice.
Contributors: R.B. co-ordinated the study and drafted the
manuscript. D.S. and K.G. contributed to the analysis and con-
tributed to the manuscript revisions. W.K., B.M. and A.P. con-
tributed to the study design and manuscript revisions. A.P. is
a guarantor.
Funding: the study was financially supported by the UMC
Groningen, The Netherlands.R E F E R E N C E S1. Bleyer WA. Cancer in older adolescents and young adults:
epidemiology, diagnosis, treatment, survival, and importance
of clinical trials. Med Pediatr Oncol 2002;38:1–10.2. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F,
Terenziani M. Childhood cancer survival trends in Europe: a
EUROCARE Working Group study. J Clin Oncol 2005;23:
3742–51.
3. Oeffinger KC, Eshelman DA, Tomlinson GE, Buchanan GR,
Foster BM. Grading of late effects in young adult survivors of
childhood cancer followed in an ambulatory adult setting.
Cancer 2000;88:1687–95.
4. Lackner H, Benesch M, Schagerl S, Kerbl R, Schwinger W,
Urban C. Prospective evaluation of late effects after childhood
cancer therapy with a follow-up over 9 years. Eur J Pediatr
2000;159:750–8.
5. Stevens MC, Mahler H, Parkes S. The health status of adult
survivors of cancer in childhood. Eur J Cancer 1998;34:694–8.
6. Meadows AT, Black B, Nesbit Jr ME, et al. Long-term survival.
Clinical care, research, and education. Cancer 1993;71:
3213–5.
7. Aaronson NK. Quality of life research in cancer clinical trials:
a need for common rules and language. Oncology
(Williston.Park) 1990;4:59–66.
8. Pemberger S, Jagsch R, Frey E, et al. Quality of life in long-
term childhood cancer survivors and the relation of late
effects and subjective well-being. Support Care Cancer
2005;13:49–56.
9. Veenstra KM, Sprangers MA, van der Eyken JW, Taminiau AH.
Quality of life in survivors with a Van Ness-Borggreve
rotationplasty after bone tumour resection. J Surg Oncol
2000;73:192–7.
10. Dolgin MJ, Somer E, Buchvald E, Zaizov R. Quality of life in
adult survivors of childhood cancer. Soc Work Health Care
1999;28:31–43.
11. Tempelaar R, De Haes JC, De Ruiter JH, Bakker D, Van Den
Heuvel WJ, Van Nieuwenhuijzen MG. The social experiences
of cancer patients under treatment: a comparative study. Soc
Sci Med 1989;29:635–42.
12. Fromm K, Andrykowski MA, Hunt J. Positive and negative
psychosocial sequelae of bone marrow transplantation:
implications for quality of life assessment. J Behav Med
1996;19:221–40.
13. Taylor SE, Lichtman RR, Wood JV. Attributions, beliefs about
control, and adjustment to breast cancer. J Pers Soc Psychol
1984;46:489–502.
14. Apajasalo M, Sintonen H, Siimes MA, et al. Health-related
quality of life of adults surviving malignancies in childhood.
Eur J Cancer 1996;32A:1354–8.
15. Breetvelt IS, Van Dam FS. Underreporting by cancer patients:
the case of response-shift. Soc Sci Med 1991;32:981–7.
16. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item
Health Survey 1.0. Health Econ 1993;2:217–27.
17. Aaronson NK, Muller M, Cohen PD, et al. Translation,
validation, and norming of the Dutch language version of the
SF-36 Health Survey in community and chronic disease
populations. J Clin Epidemiol 1998;51:1055–68.
18. Vanderzee KI, Sanderman R, Heyink JW, de Haes H.
Psychometric qualities of the RAND 36-item health survey 1.0:
a multidimensional measure of general health status. Int J
Behav Med 1996;3:104–22.
19. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria:
version 2.0. an improved reference for grading the acute
effects of cancer treatment: impact on radiotherapy. Int J
Radiat Oncol Biol Phys 2000;47:13–47.
20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0:
development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol
2003;13:176–81.
21. Holmes GE, Baker A, Hassanein RS, et al. The availability of
insurance to long-time survivors of childhood cancer. Cancer
1986;57:190–3.
130 E U R O P E A N J O U R N A L O F C A N C E R 4 3 ( 2 0 0 7 ) 1 2 2 –1 3 022. Teta MJ, Del Po MC, Kasl SV, Meigs JW, Myers MH, Mulvihill JJ.
Psychosocial consequences of childhood and adolescent
cancer survival. J Chronic Dis 1986;39:751–9.
23. Elkin TD, Phipps S, Mulhern RK, Fairclough D. Psychological
functioning of adolescent and young adult survivors of
pediatric malignancy. Med Pediatr Oncol 1997;29:582–8.
24. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of
young adult survivors of childhood cancer: a report from the
Childhood Cancer Survivor Study. Ann Fam Med 2004;2:61–70.25. Oeffinger KC. Childhood cancer survivors and primary care
physicians. J Fam Pract 2000;49:689–90.
26. Friedman DL, Freyer DR, Levitt GA. Models of care for
survivors of childhood cancer. Pediatr Blood Cancer
2006;46:159–68.
27. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult
long-term survivors of childhood cancer: a report from the
Childhood Cancer Survivor Study. JAMA 2003;290:
1583–92.
